Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXA-RSV-f Phase 1 in Healthy Volunteers
NCT02830932Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Jun 2016
- Primary completion
- Sep 2016
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VXA-RSV-f in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Vaxart, Inc. Primary endpoint: Systemic Reactogenicity of VXA-RSV-f vaccine at Day 7. Started Jun 2016; status: completed.
02
Drugs
VXA-RSV-f
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02830932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02830932.